Ahangari D, Ngendahayo P, Colinet B, Roquet-Gravy P-P
Service de dermatologie, grand hôpital de Charleroi (GHDC), Charleroi, Belgique; Rue de Villers, 1, 6280 Loverval, Belgique.
Service d'anatomopathologie, Institut de pathologie et génétique (IPG), avenue Georges-Lemaitre, 25, 6041 Charleroi, Belgique.
Ann Dermatol Venereol. 2020 Mar;147(3):202-206. doi: 10.1016/j.annder.2019.10.030. Epub 2020 Feb 3.
Sweet syndrome is a neutrophilic dermatosis and is often idiopathic, although its onset may be drug-induced or paraneoplastic. The purpose of this case report is to describe the very first occurrence of Sweet syndrome following erlotinib intake in a patient diagnosed with lung adenocarcinoma.
We observed Sweet syndrome, as assessed by clinical, laboratory and histological examination, in a middle-aged female patient presenting lung adenocarcinoma diagnosed three years prior to her cutaneous symptoms.
Given the extremely long time between the diagnosis of lung cancer and the onset of Sweet syndrome, as well as the occurrence of skin lesions during administration of the medication and their subsidence after drug withdrawal, we suggest a possible link between this particular EGFR tyrosine kinase inhibitor and the patient's neutrophilic dermatological signs. To our knowledge this association has not previously been described in the medical literature.
Sweet综合征是一种嗜中性皮病，通常为特发性，但其发病可能由药物引起或与肿瘤相关。本病例报告的目的是描述一名被诊断为肺腺癌的患者在服用厄洛替尼后首次出现Sweet综合征的情况。
我们通过临床、实验室和组织学检查评估，在一名中年女性患者中观察到Sweet综合征，该患者在出现皮肤症状三年前被诊断为肺腺癌。
鉴于肺癌诊断与Sweet综合征发病之间的时间间隔极长，以及在用药期间出现皮肤病变且停药后消退，我们认为这种特定的表皮生长因子受体酪氨酸激酶抑制剂与患者的嗜中性皮肤病体征之间可能存在关联。据我们所知，这种关联此前在医学文献中尚未有描述。
